The prevalence of reduced zidovudine susceptibility in zidovudine-naive, antiretroviral-experienced HIV-1-infected patients

HIV Medicine

Volumn 4, Issue 4, 2003, Pages 305-310

  Gilleece, Yvonne ^a,d   Torti, C ^b   Mandalia, S ^a   Gazzard, B G ^a   Pillay, D ^c   Pozniak, A L ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d St Stephen's Centre   (United Kingdom)

Author keywords

Cross resistance; Nucleoside reverse transcriptase inhibitors; Stavudine; Zidovudine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANAMNESIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS RESISTANCE; DATA BASE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MEDICAL RECORD; PREVALENCE; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZIDOVUDINE;

EID: 0142186264     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2003.00163.x     Document Type: Article

References (29)

1. Durant J, Clevenbergh P, Halfon et al. Drug resistance genotyping in HIV-1 therapy. Lancet 2001; 353: 2195-2199.
2. Harrigan PR, Hertogs K, Verbiest et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999; 13: 1863-1871.
3. Miller V, Phillips A, Rottmann C et al. Dual resistance to zidovudine and lamivudine in patients treated with dual zidovudine-lamivudine therapy. J Infect Dis 1998; 177: 1521-1532.
4. Zolopa AR, Shafer RW, Warford A et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Int Med 1999; 131: 813-821.
5. Hirsch MS, Brun-Vezinet F, D'Aquila RT et al. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendation of an international AIDS Society-USA panel. J Am Med Assoc 2000; 283: 2417-2426.
6. Katlama C, Valantin MA, Matheron S et al. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection. Ann Intern Med 1998; 129: 525-531.
7. Soriano V, Dietrich U, Villalba N et al. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy. AIDS 1997; 11: 696-697.
8. Lin PF, Gonzalez CJ, Griffith B et al. Stavudine resistance: an update on susceptibility following prolonged therapy. Antiviral Ther 1999; 4: 21-28.
9. Descamps D, Calvez V, Collin G et al. Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis. J Clin Microbiol 1998; 36: 2143-2145.
10. Lin PF, Samanta H, Rose RE et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994; 170: 1157-1164.
11. Pellegrin I, Izopet J, Reynes J et al. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. AIDS 1999; 13: 1705-1709.
12. Coakley EP, Gillis JM, Hammer S. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000; 14: F9-F15.
13. De Mendoza C, Soriano V, Briones C et al. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine. J Acquir Immune Defic Syndr 2000; 23: 279-281.
14. Scarsella A, Kaiser J, Ross L et al. Reverse transcriptase (RT) mutation patterns from ZDV-naive subjects failing D4T-containing regimens. XIII International AIDS Conference. Durban, South Africa, July 2000 [Abstract 3014].
15. Monno L, Appice A, Scarabaggio T, Di Stefano M, Pastore G, Angarano G. Mutations in the reverse transcriptase gene of HIV type 1 from subjects after stavudine-didanosine dual therapy. Acquir Immune Defic Syndr Res Hum Retroviruses 2000; 16: 821-823.
16. Harrigan PR, Larder BA. Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates. Antimicrob Agents Chemother 2002; 46: 909.
17. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993; 365: 671-673.
18. Baxter J et al. Final results of CPCRA 046: a pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Antiviral Ther 1999; 4 (Suppl. 1): 43.
19. Larder BA, Kemp SD, Hertogs K. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (Virtual/Phenotype™). Antiviral Ther 2000; 5 (Suppl. 3): 49.
20. Hertogs K, de Bethune MP, Miller V et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42: 269-276.
21. Larder BA et al. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database. Antiviral Ther 1999; 4 (Suppl. 1): 41.
22. Calvez V, Costagliola D, Descamps D et al. Impact of stavudine phenotype and thymidine analogue mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antiviral Ther 2002; 7: 211-218.
23. Becker S, Fusco G, Hansen N et al. NRTI sequencing - prior D4T therapy impairs viral load response to AZT-containing regimens to a greater extent than AZT prior to D4T: updated results from the CHORUS HIV cohort study. Third International Workshop on HIV Drug Resistance, Treatment Strategies. Toronto, Canada, May 1999 [Abstract 009].
24. Montaner JS, Mo T, Raboud JM et al. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine. J Infect Dis 2000; 181: 729-731.
25. Grassi J, Becher F, Pruvost A et al. Intracellular metabolism of AZT leads to the production of significant levels of d4T triphosphate in HIV-infected patients. Sixth International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2002 [Abstract 8.3].
26. Trouplin V, Mammano F, Clavel F et al. Why does stavudine select zidovudine resistance mutations in vivo? 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 471].
27. Maxeiner HG, Keulen W, Schuurman R et al. Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients. J Infect Dis 2002; 185: 1070-1076.
28. Mouroux M, Descamps D, Izopet A et al. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naïve patients receiving stavudine plus lamivudine combination therapy. Antiviral Ther 2001; 6: 179-183.
29. Shulman NS, Winters MA, Shafer RW et al. Subtle changes in susceptibility to D4T predict virologic response to D4T monotherapy after AZT treatment. Fifth International Workshop on Drug Resistance and Treatment Strategies. Scottsdale, AZ, June 2001 [Abstract 124].